Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases
| Autor: | Dan Lipsker, Olivier Dereure, Nicolas Terrail, B. Bergeret, M. Dandurand, Valerie Reymann, Didier Bessis, Aurélie Du-Thanh |
|---|---|
| Přispěvatelé: | Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHU Strasbourg |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Best Overall Response Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Refractory MESH: Lenalidomide medicine Lupus Erythematosus Cutaneous Humans Lenalidomide ComputingMilieux_MISCELLANEOUS MESH: Treatment Outcome 030203 arthritis & rheumatology MESH: Humans business.industry Low dose MESH: Thalidomide MESH: Lupus Erythematosus Cutaneous University hospital Institutional review board 3. Good health Thalidomide Infectious Diseases Treatment Outcome Relative risk Cutaneous Lupus Erythematosus business [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology medicine.drug |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology Journal of the European Academy of Dermatology and Venereology, Wiley, 2021, 35 (2), pp.e113-e115. ⟨10.1111/jdv.16839⟩ |
| ISSN: | 1468-3083 0926-9959 |
| DOI: | 10.1111/jdv.16839⟩ |
| Popis: | Lenalidomide (LND), a synthetic thalidomide analog mainly used in haematological malignancies has proved efficient and well-tolerated in small case series of refractory Cutaneous Lupus Erythematosus (CLE). A retrospective survey of CLE patients treated with low-dose LND in three institutional Departments of Dermatology was conducted to further assess the benefit/risk ratio of this molecule in this setting (Institutional Review Board for ethical issues of University Hospital of Montpellier 2018_IRB-MTP_11-01). Primary endpoints were best overall response (BOR) obtained with initial dosage or after dose adjustment and time to achieve BOR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text